Literature DB >> 3928560

Combination antitumor therapy with rabbit tumor necrosis factor and chemo- and immuno-therapeutic agents against murine tumors.

T Gatanaga, K Takahashi, M Yamazaki, D Mizuno, S Abe.   

Abstract

The antitumor activity of partially purified rabbit tumor necrosis factor (TNF) in combination with lentinan or chemotherapeutic agents was tested. Partially purified TNF was obtained from TNF-containing rabbit sera by salt precipitation and ion-exchange chromatography. Its specific activity, determined in vitro as its cytotoxic activity against L929 cells in the presence of actinomycin D, was 10(5) U/mg protein or about 30-fold that of the crude rabbit sera. The growths of MH134 hepatoma in C3H/He mice and Lewis lung carcinoma in C57BL/6 mice were partially inhibited by intratumoral administration of a suboptimal dose of the TNF preparation. Additional treatment with lentinan, actinomycin D, mitomycin C or adriamycin significantly increased the antitumor activity. In particular, combination therapy with TNF and lentinan was very effective against MH134 hepatoma without having detectable side-effects, showing that lentinan expanded the therapeutical potential of TNF. These results are discussed in relation to our previous results on combination antitumor therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928560

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  5 in total

1.  Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.

Authors:  T Gatanaga; C D Hwang; W Kohr; F Cappuccini; J A Lucci; E W Jeffes; R Lentz; J Tomich; R S Yamamoto; G A Granger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.

Authors:  Holly J Meany; Nita L Seibel; Junfeng Sun; Jerry Z Finklestein; Judith Sato; John Kelleher; Paul Sondel; Gregory Reaman
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

3.  Intratumoral induction of tumour necrosis factor by systemic administration of Bordetella pertussis vaccine.

Authors:  H Minagawa; H Kobayashi; H Yoshida; M Teranishi; A Morikawa; S Abe; H Oshima; D I Mizuno
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

4.  Local induction of a cytotoxic factor in a murine tumour by systemic administration of an antitumour polysaccharide, MGA.

Authors:  K Takahashi; Y Watanuki; M Yamazaki; S Abe
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

5.  Enhancement of cytotoxicity of cisplatin in vitro by recombinant human tumor necrosis factor and/or recombinant human interferon-alpha, -beta and -gamma.

Authors:  C M Kim; W S Hong; J O Lee; T W Kang; Y W Kim; J K Song; T K Yun; C Y Kim
Journal:  Jpn J Cancer Res       Date:  1989-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.